Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00361452 |
Recruitment Status :
Terminated
First Posted : August 8, 2006
Last Update Posted : August 8, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rsv Bronchiolitis | Drug: nebulized epinephrine and nebulized albuterol | Phase 4 |
Inpatient Infants younger than 2 years of age with first episode of RSV bronchiolitis will be randomly assigned to treatment with nebulized epinephrine (1 mg diluted with 3 ml of 0.9% saline) or nebulized albuterol (2.5 mg diluted with 3.5 ml of 0.9% saline). Both solutions will be provided in identical containers.
Clinical assessment and clinical score will be done before treatment, 10 and 30 minutes after treatment. The following parameters were recorded at each time point, wheezing, respiratory distress, O2 saturation, respiratory rate and heart rate. Computerized lung sounds as well, will be recorded before treatment, 10 and 30 minutes after treatment via 4 contact sensors attached to the chest.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study |
Study Start Date : | December 2000 |
Study Completion Date : | May 2001 |

- respiratory clinical score
- computerized quantification of wheezing and crackles

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 1 Year (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Under one year of age
- first episode of wheezing and dyspnea
- RSV antigen detected by ELISA
- parents signed informed consent.
Exclusion Criteria:
- infants with chronic lung disease
- cardiac disease
- other chronic conditions.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00361452
Israel | |
Pediatric Ward, Rambam Medical Centre | |
Haifa, Israel, 31096 |
Principal Investigator: | LEA BENTUR, MD | Rambam medical centre, pediatric pulmonary unit, HAIFA |
ClinicalTrials.gov Identifier: | NCT00361452 |
Other Study ID Numbers: |
epinephrine_albuterol_rsv.ctil |
First Posted: | August 8, 2006 Key Record Dates |
Last Update Posted: | August 8, 2006 |
Last Verified: | November 2000 |
Bronchiolitis Bronchitis Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Tract Infections Epinephrine Albuterol Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Physiological Effects of Drugs Adrenergic beta-Agonists Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Mydriatics Sympathomimetics Vasoconstrictor Agents Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists |